Tagged with BioTech

Canada At the company’s 40th anniversary, Biogen’s Canadian head Marina Vasiliou gives an insight into her priorities as new managing director, her approach to building relationships with all stakeholders in the healthcare system to ensure access to Biogen’s innovative treatments, and explains how the portfolio of the neuroscience leader is perfectly…

India Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in the next few years and an increasing global focus on improving healthcare access and the cost of care. Against this…

Poland Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment strategy to assure the company’s impressive growth. Furthermore, he surveys the Polish R&D landscape and discusses the importance of a…

Canada Oliver Technow, president at BioVectra, highlights the company’s recent developments; amongst those a significant investment in a manufacturing site near Halifax. The resulting increase in manufacturing capacity by 40 percent will add to BioVectra’s position as the largest biotechnology company on Prince Edward Island, a historic location the CDMO is…

Canada Michel Fortin, president and CEO of Prevtec Microbia, a global biotech player founded in Saint-Hyacinthe, outside of Montréal, analyzes the opportunities in the global animal health industry, and how Prevtec Microbia has positioned itself to seize those by developing technologies that are alternatives to the usage of antibiotics in animal…

Poland Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way. Moreover, she highlights the importance of achieving reimbursement for three key products for Multiple Sclerosis and Oncology as well as…

Canada David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the SHIP1 enzyme, with a focus on treating interstitial cystitis/bladder pain syndrome. Other applications may include blood cancers and chronic prostatitis/chronic…

Poland Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the first ever CDK8 inhibitor for acute myeloid leukaemia with great opportunities for further indications and development. Furthermore, he highlights the…

Switzerland Laurent-Dominique Piveteau, CEO of Swiss medtech innovator Debiotech, discusses digital disruption, Swiss innovation, and future growth drivers. As well as being CEO of Debiotech, you also lecture courses at EPFL on “Economics of Innovation in the Biomedical Industry”. What are your thoughts on the incorporation of disruptive technologies in the…

India A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar for trastuzumab and the sixth approved biosimilar in the US overall, and how Biocon is implementing a low-value high-volume model…

Switzerland Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?”   We aspire to move the company and the relationship with our customers from being a functional service provider to the strategic partner…

Brazil Sameer Savkur, country manager of Biogen Brazil, provides insights into the key specificities of the Brazilian pharmaceutical ecosystem and documents the great successes of Biogen affiliate in working hand-in-hand with all key public and regulatory stakeholders in Brazil, as recently illustrated with Biogen’s innovative treatment for spinal muscular atrophy (SMA),…